Clinical Trials Directory

Trials / Terminated

TerminatedNCT00667095

Over Active Bladder Instillation Study - Botox

Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly better improvement of their OAB symptoms when compared to a similar group of women with OAB who receive instillation of DMSO only.

Detailed description

The primary objective of this study is to evaluate the efficacy of catheter-based instillation of a solution of Botox/DMSO as a novel method for treating women with overactive bladder (OAB) and secondary urinary incontinence who have failed oral pharmacologic therapy. This study will test the broad hypothesis that administration of Botox/DMSO instillations into the bladder with a urethral catheter can significantly improve symptoms and quality of life in patients with OAB when compared to DMSO installations alone. Explicitly, we hypothesize that scores on the validated Incontinence Quality of Life (I-QOL) questionnaire of women with OAB who receive Botox/DMSO instillation will be much improved at three-month follow-up compared to similar women receiving DMSO instillation alone. Our long-term goal is to offer women with detrusor hyperreflexia or OAB a less invasive alternative to surgery and an alternative to anticholinergic by mouth medications. In support of this effort, we are proposing a randomized, double-blind, placebo controlled clinical trial to be conducted in the Department of Urology at Mayo Clinic, Jacksonville, Florida. Note: The study was terminated early in July of 2011 due to an extended medical absence of the Principal Investigator.

Conditions

Interventions

TypeNameDescription
DRUGBotox InstillationBotox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
DRUGDMSO InstillationDMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.

Timeline

Start date
2008-04-01
Primary completion
2012-01-01
Completion
2012-01-01
First posted
2008-04-25
Last updated
2014-07-11
Results posted
2014-07-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00667095. Inclusion in this directory is not an endorsement.